| Not Yet Recruiting | ACT for Veterans With IBD and Mental Health Challenges NCT07397195 | VA Office of Research and Development | N/A |
| Not Yet Recruiting | Digital Mind Body Intervention Among Black and Hispanic Patients Living With Inflammatory Bowel Disease NCT06510296 | Montefiore Medical Center | N/A |
| Not Yet Recruiting | A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease NCT07403968 | Takeda | Phase 2 |
| Not Yet Recruiting | A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balinatunfib in Participants With Cr NCT07222189 | Sanofi | Phase 2 |
| Not Yet Recruiting | Repetitive Transcranial Magnetic Stimulation Combined With Anti-inflammatory Diet in Crohn's Disease NCT07531342 | Cairo University | N/A |
| Not Yet Recruiting | Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease NCT07417696 | Chinese Medical Association | Phase 4 |
| Recruiting | A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's NCT07421258 | AbbVie | — |
| Recruiting | 68Ga-FAPI-46 PET/CT for Assessing Small Bowel Fibrostenosis in Crohn's Disease NCT07273188 | Mayo Clinic | EARLY_Phase 1 |
| Recruiting | A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Sev NCT07184944 | Sanofi | Phase 3 |
| Completed | A Study on Infections in Adults With Ulcerative Colitis/Crohn's Disease NCT07250815 | Takeda | — |
| Not Yet Recruiting | The Effect of Vascular Imaging Devices on Success Rates of Peripheral Vascular Access in Pediatric Patients NCT07315711 | Sibel Seçkin Pehlivan | — |
| Recruiting | A Study to Observe Real-world Evidence of Guselkumab Treatment in Participants With Ulcerative Colitis and Cro NCT07242248 | Janssen-Cilag Ltd. | — |
| Recruiting | A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's D NCT06405087 | Takeda | Phase 3 |
| Recruiting | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Seve NCT07184931 | Sanofi | Phase 3 |
| Recruiting | A Study to Generate Real-world Evidence of Guselkumab Effectiveness in Inflammatory Bowel Disease in Germany NCT07102368 | Janssen-Cilag G.m.b.H | — |
| Recruiting | A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participa NCT07073079 | AbbVie | — |
| Recruiting | Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Dise NCT06937099 | Eli Lilly and Company | Phase 3 |
| Recruiting | A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease NCT07113522 | Mirador Therapeutics, Inc. | Phase 2 |
| Recruiting | A Study to Investigate Efficacy and Safety of SAR442970 in Patients With Crohn's Disease NCT06958536 | Sanofi | Phase 2 |
| Recruiting | A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) NCT06764615 | Takeda | Phase 2 |
| Recruiting | Vibration Exercise for Crohn's to Observe Response NCT06211400 | University of Hertfordshire | N/A |
| Enrolling By Invitation | Enabling Microbiomics- Driven Personalized Nutrition NCT06657001 | Mayo Clinic | — |
| Recruiting | A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting NCT06581328 | Takeda | Phase 4 |
| Recruiting | Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease NCT06925594 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | Feasibility of a Minimally Invasive Diagnostic Algorithm in Suspected Crohn's Disease NCT06882993 | Esbjerg Hospital - University Hospital of Southern Denmark | N/A |
| Recruiting | A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease NCT06100289 | Takeda | Phase 3 |
| Recruiting | A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease NCT06227910 | Takeda | Phase 3 |
| Recruiting | Study Evaluating AZD7798 for Treatment in Crohn's Disease Patients With an Ileostomy NCT06681324 | AstraZeneca | Phase 2 |
| Recruiting | A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease. NCT06637631 | Sanofi | Phase 2 |
| Recruiting | Behavioral Therapy for Crohn's Disease NCT06512597 | Icahn School of Medicine at Mount Sinai | N/A |
| Recruiting | Comparison of Vedolizumab Treatment to Adalimumab Dose Intensification in Crohn's Disease Patients With Loss o NCT06180382 | Centre Hospitalier Universitaire de Saint Etienne | Phase 4 |
| Recruiting | Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease NCT06274554 | Weill Medical College of Cornell University | Phase 3 |
| Recruiting | Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowe NCT06581042 | AbbVie | — |
| Recruiting | Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease NCT06548542 | AbbVie | Phase 2 |
| Recruiting | Helmsley 3.0: Abbreviated MRE NCT06533228 | Children's Hospital Medical Center, Cincinnati | — |
| Recruiting | Beta-Hydroxybutyrate Feasibility Treating IBD NCT06351124 | University of Texas at Austin | Phase 1 / Phase 2 |
| Recruiting | Crohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately NCT06332534 | AbbVie | Phase 3 |
| Recruiting | Impact of Diet and Lifestyle Modification on the Intestinal Barrier Integrity in Crohn's Disease NCT06719778 | Universität Duisburg-Essen | N/A |
| Recruiting | A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease NCT06226883 | Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) | Phase 2 |
| Completed | Study of Oral Upadacitinib to Assess Change in Disease Activity and Adverse Events in Adult Participants With NCT06459297 | AbbVie | — |
| Recruiting | A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe NCT06430801 | Merck Sharp & Dohme LLC | Phase 3 |
| Not Yet Recruiting | TOward a Better Understanding of the autoPhagy Machinery for the Identification of Potential Novel Biomarkers NCT06244849 | Hospices Civils de Lyon | N/A |
| Not Yet Recruiting | Evaluation of Enteral Nutrition Biscuits for Inducing Remission in Moderate-to-severe Crohn's Disease NCT06362863 | Ping An | N/A |
| Recruiting | A Pilot Study to Assess the Safety, Tolerability, and Efficacy of Virtual Reality for the Treatment of Abdomin NCT06647615 | Mayo Clinic | N/A |
| Recruiting | A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's D NCT06045754 | Takeda | Phase 4 |
| Recruiting | Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients NCT06408935 | Janssen-Cilag Ltd. | Phase 3 |
| Recruiting | Evaluate the Distribution and Dynamic Behavior of TH-SC01 Cells in Vivo in Patients With Perianal Fistula NCT06429241 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease NCT07504510 | Sixth Affiliated Hospital, Sun Yat-sen University | — |
| Recruiting | VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective NCT06249555 | Alimentiv Inc. | — |
| Recruiting | A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease NCT05509777 | Eli Lilly and Company | Phase 3 |
| Recruiting | A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease NCT05923073 | Janssen Research & Development, LLC | Phase 3 |
| Recruiting | A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Mode NCT06233461 | Takeda | Phase 2 |
| Recruiting | MRE Predictors of Disease Relapse After Stopping Biologics NCT06124287 | University College, London | — |
| Active Not Recruiting | Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Mode NCT05930275 | AbbVie | — |
| Unknown | IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study NCT06573944 | The Third Xiangya Hospital of Central South University | — |
| Recruiting | Non-invasive Assessment of RECTUM (POUCH) by US (RECT-US) in a Cohort of IBD Patients NCT06407674 | IRCCS San Raffaele | — |
| Recruiting | Efficacy and Safety of Upadacitinib in Inflammatory Bowel Disease NCT06780683 | Xiang Gao | — |
| Recruiting | A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizuma NCT05995353 | AbbVie | Phase 3 |
| Recruiting | Longitudinal Study on Bacterial Production of LPC and LPA in Patients With Inflammatory Bowel Disease NCT06548399 | McMaster University | — |
| Active Not Recruiting | A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatme NCT06063967 | AbbVie | Phase 3 |
| Completed | An Observational Study to Assess Participant-Reported Real-World Experience of Risankizumab On-body Injector ( NCT06126146 | AbbVie | — |
| Recruiting | Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CD NCT06064864 | Asan Medical Center | N/A |
| Recruiting | A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in Sou NCT05428345 | Takeda | — |
| Completed | Positron Emission Tomography (PET) Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7 NCT06053424 | AstraZeneca | Phase 1 |
| Terminated | Study of ExoFlo for the Treatment of Perianal Fistulas NCT05836883 | Direct Biologics, LLC | Phase 1 / Phase 2 |
| Recruiting | An Observational Study to Assess Change in Disease Activity and Adverse Events in Adolescent and Adult Partici NCT06023030 | AbbVie | — |
| Recruiting | Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research NCT04806620 | Brain Inflammation Collaborative | — |
| Recruiting | Clinical Efficacy of Ustekinumab in Crohn's Disease NCT06523647 | Kazakhstan Scientific Society for Study of intestine diseases | — |
| Recruiting | A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease NCT05837897 | Takeda | Phase 3 |
| Recruiting | Evaluation of Molecular Mechanisms of Non-response to Therapy in Patients With Inflammatory Bowel Disease NCT05733845 | Central Hospital, Nancy, France | N/A |
| Active Not Recruiting | An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Mode NCT05841537 | AbbVie | — |
| Recruiting | The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease NCT06006039 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | — |
| Recruiting | A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) NCT05442567 | Takeda | Phase 3 |
| Recruiting | Intermittent Caloric Restriction in Patients With Mild to Moderate Crohn's Disease NCT05683730 | Central Hospital, Nancy, France | N/A |
| Active Not Recruiting | A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program ( NCT05626088 | Takeda | — |
| Completed | A Study of Vedolizumab in Adults With Crohn's Disease (CD) NCT05192863 | Takeda | — |
| Terminated | A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection NCT05784129 | Janssen Research & Development, LLC | Phase 3 |
| Active Not Recruiting | Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease NCT03992469 | Icahn School of Medicine at Mount Sinai | Phase 1 |
| Active Not Recruiting | Capsule & Omics for pRedicting Exacerbation of Crohn's Disease NCT06362174 | Sheba Medical Center | — |
| Withdrawn | The Role of Gut Microbiome in Predicting Comorbidities and Complications in Children With Inflammatory Bowel D NCT05652491 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Terminated | Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy NCT04456517 | Vanderbilt University Medical Center | Phase 2 |
| Withdrawn | Exclusive Enteral Nutrition vs. Infliximab in Chinese CD Patients NCT04530877 | Children's Hospital of Fudan University | Phase 4 |
| Recruiting | Use of Crohn's Disease Exclusion Diet on Top of Standard Therapy Versus Standard Therapy Alone in Unstable Ped NCT04777656 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | A Study in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) Receiving Vedolizumab in Real-World Pra NCT05384080 | Takeda | — |
| Active Not Recruiting | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Activ NCT05242471 | Janssen Research & Development, LLC | Phase 2 |
| Completed | A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity NCT05394805 | AbbVie | — |
| Completed | The MOTOR-CD Trial NCT05363930 | Asian Institute of Gastroenterology, India | N/A |
| Withdrawn | A Study of Oral Foralumab in Participants With Moderate to Severely Active Crohn's Disease NCT05028946 | Tiziana Life Sciences LTD | Phase 1 |
| Withdrawn | Stem Cells for the Treatment of Pouchitis NCT05578508 | The Cleveland Clinic | Phase 1 |
| Completed | A Study of Ustekinumab Treatment in Children With Crohn's Disease NCT05242458 | Janssen Research & Development, LLC | — |
| Terminated | Evaluation of the Response of Itraconazole and Terbinafine Therapy in Subjects With Crohn's Disease NCT05049525 | Montreal Heart Institute | Phase 2 |
| Terminated | A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Ag NCT05068284 | AbbVie | Phase 2 |
| Completed | A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease NCT05626023 | Jiangsu Topcel-KH Pharmaceutical Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Survey of Darvadstrocel in People With Crohn's Disease NCT05113095 | Takeda | — |
| Completed | Empagliflozin as a Treatment for Severe Congenital Neutropenia Due to G6PC3 Deficiency NCT05078879 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Assessment of the Safety, Tolerability, and Pharmacokinetic of HM201 NCT05088369 | Syneos Health | Phase 1 |
| Withdrawn | Safety and Efficacy of Oral BT-11 in Crohn's Disease Patients With Moderate to Severe Disease NCT05057273 | NImmune Biopharma | Phase 2 |
| Active Not Recruiting | Seeded Cells on Matrix Plug Treating Crohn's Perianal Fistulas (STOMP-II) NCT04847739 | Avobis Bio, LLC | Phase 2 |
| Terminated | Synbiotics and Post-op Crohn's Disease NCT04804046 | University of Alberta | N/A |
| Terminated | A Study of Darvadstrocel for Treating Complex Perianal Fistulas in Children and Teenagers With Crohn's Disease NCT04701411 | Takeda | Phase 3 |
| Active Not Recruiting | A Study of CDPATH™ to Help Manage and Treat Crohn's Disease NCT04809363 | Takeda | Phase 4 |
| Active Not Recruiting | A Study of Intravenous Vedolizumab Administered Every 4 Weeks in Japanese Participants With Moderate to Severe NCT04738942 | Takeda | Phase 3 |
| Withdrawn | Mesenchymal Stem Cells for the Treatment of Pouch Fistulas in Crohn's NCT04073472 | The Cleveland Clinic | Phase 1 |
| Withdrawn | A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With NCT04643483 | UCB Biopharma SRL | Phase 3 |
| Completed | A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD) NCT05596422 | Takeda | — |
| Recruiting | A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis NCT04844606 | Eli Lilly and Company | Phase 3 |
| Completed | Diet in Pediatric Crohn´s Disease Treated With Biologics NCT05034458 | Hospital Italiano de Buenos Aires | N/A |
| Terminated | Efficacy and Safety of Oral BT-11 in Moderate to Severe Crohn's Disease NCT03870334 | NImmune Biopharma | Phase 2 |
| Completed | Effect of Vitamin D Supplementation on the Efficacy of Ustekinumab in the Treatment of Crohn's Disease NCT05867784 | Second Affiliated Hospital of Wenzhou Medical University | — |
| Withdrawn | Study to Evaluate Safety, Tolerability and Efficacy of GSK2330811 in Crohn's Disease NCT04151225 | GlaxoSmithKline | Phase 2 |
| Completed | Non Invasive Characterization of Pediatric Inflammatory Bowel Diseases Using Multispectral Optoacoustic Tomogr NCT04650867 | University of Erlangen-Nürnberg Medical School | — |
| Unknown | Pilot Study of an Online Therapeutic Education Program for Patients With Inflammatory Bowel Disease NCT03648398 | Central Hospital, Nancy, France | N/A |
| Unknown | Safety and Efficacy of Artesunate & Curcumin in Crohn's Disease NCT04713631 | Sanjay Gandhi Postgraduate Institute of Medical Sciences | Phase 2 |
| Terminated | A Study of Darvadstrocel in Adults With Crohn's Disease and Complex Perianal Fistula NCT04118088 | Takeda | Phase 4 |
| Active Not Recruiting | USTekinumab in Fistulising Perianal Crohn's Disease (USTAP) NCT04496063 | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Phase 4 |
| Unknown | A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease. NCT04939337 | Jinling Hospital, China | Phase 1 |
| Unknown | Exploring the Effects of Vitamin D Supplementation on the Chronic Course of Patients With Crohn's Disease With NCT04308850 | Second Affiliated Hospital of Wenzhou Medical University | EARLY_Phase 1 |
| Unknown | Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D NCT04276636 | Second Affiliated Hospital of Wenzhou Medical University | EARLY_Phase 1 |
| Recruiting | Pregnancy and Inflammatory Bowel Disease NCT07377188 | Centre Hospitalier Universitaire, Amiens | — |
| Completed | Impact of Telemonitoring in the Management of Complex IBD in Spain: M-TECCU NCT06031038 | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | N/A |
| Terminated | Predicting Medication Response for Autoimmune Disease NCT04995783 | Coral Genomics, Inc. | — |
| Completed | ENhanced Recovery in CHildren Undergoing Surgery NCT04060303 | Northwestern University | Phase 3 |
| Active Not Recruiting | A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease NCT04232553 | Eli Lilly and Company | Phase 3 |
| Completed | A Study in Pregnant Women With Chronic Inflammatory Diseases Treated With Cimzia (Certolizumab Pegol) NCT04163016 | UCB Biopharma SRL | Phase 1 |
| Completed | A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome NCT04254783 | AbbVie | Phase 1 |
| Unknown | The Effect of Joint Transition Visits on Quality of Life in Inflammatory Bowel Diseases (TRANS-IBD) NCT04290156 | University of Pecs | N/A |
| Completed | Mesenteric SParIng Versus Central mesenterectomY in Ileocolic Resection for Terminal Ileitis in Crohn's Diseas NCT04538638 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | N/A |
| Terminated | Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammat NCT03850509 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |
| Completed | MICISPORT Survey : Questionnaire NCT04297566 | University Hospital, Montpellier | — |
| Terminated | Open-label Extension Study of Brazikumab in Crohn's Disease NCT03961815 | AstraZeneca | Phase 3 |
| Terminated | A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moder NCT04173273 | Pfizer | Phase 3 |
| Withdrawn | AlloGeneic Human Mesenchymal Stem Cells (hMSC) in PAtients With FistuLizing Crohn's Disease Via PErifistula iN NCT02677350 | Joshua M Hare | Phase 1 |
| Completed | Long-term Follow-up Study With Darvadstrocel in the Treatment of Complex Perianal Fistula NCT04075825 | Takeda | Phase 3 |
| Withdrawn | Autologous Transplant Targeted Against Crohn's NCT04154735 | Northwestern University | Phase 2 |
| Completed | CT-P13 (Infliximab) Subcutaneous Administration in Patients With Moderately to Severely Active Crohn's Disease NCT03945019 | Celltrion | Phase 3 |
| Completed | Precision Crohn's Disease Management Utilizing Predictive Protein Panels (ENvISION) NCT04131504 | Children's Hospital Medical Center, Cincinnati | — |
| Completed | Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD) NCT04852666 | University of North Carolina, Chapel Hill | — |
| Completed | A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease NCT03926130 | Eli Lilly and Company | Phase 3 |
| Active Not Recruiting | Specified Drug-Use Survey on Vedolizumab for IV Infusion 300 mg [Crohn's Disease] NCT04002180 | Takeda | — |
| Completed | Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease NCT03890445 | Sandoz | — |
| Completed | Cell Surface Marker Expression in Autoimmune Diseases NCT03757065 | Alpine Immune Sciences, Inc. | — |
| Completed | A Phase II Study in Patients With Moderate to Severe Active Crohn's Disease NCT03677648 | Reistone Biopharma Company Limited | Phase 2 |
| Completed | A Study of E6011 in Participants With Active Crohn's Disease NCT03733314 | EA Pharma Co., Ltd. | Phase 2 |
| Completed | Infliximab Biosimilar "Pfizer" Drug Use Investigation (Crohn's Disease or Ulcerative Colitis) NCT03884439 | Pfizer | — |
| Terminated | Efficacy and Safety Study of Ontamalimab as Maintenance Treatment in Participants With Moderate to Severe Croh NCT03627091 | Shire | Phase 3 |
| Terminated | An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderat NCT03650413 | Genentech, Inc. | Phase 2 |
| Completed | A Study on the Associations of Toll-like Receptor 5 Gene Polymorphisms With Crohn's Disease in Chinese Patient NCT07035678 | Second Affiliated Hospital of Wenzhou Medical University | — |
| Completed | Assessment of Nutritional Status of Patients With Crohn's Disease NCT03871634 | Harokopio University | — |
| Terminated | An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn' NCT03759288 | AstraZeneca | Phase 2 / Phase 3 |
| Withdrawn | Vedolizumab Post Op Study NCT02834754 | Marc Schwartz | Phase 2 |
| Unknown | Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs NCT03729674 | McGill University Health Centre/Research Institute of the McGill University Health Centre | — |
| Terminated | Efficacy and Safety of TD-1473 in Crohn's Disease NCT03635112 | Theravance Biopharma | Phase 2 |
| Terminated | Exclusive Enteral Nutrition and Corticosteroids Therapy in Crohn's Disease (EENCD) NCT03833596 | McMaster University | Phase 4 |
| Terminated | Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's NCT03559517 | Shire | Phase 3 |
| Completed | Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or C NCT03196427 | Takeda | Phase 2 |
| Terminated | Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's NCT03566823 | Shire | Phase 3 |
| Terminated | An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's NCT03599622 | Bristol-Myers Squibb | Phase 2 |
| Completed | One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study NCT03662919 | Biogen | — |
| Terminated | Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients NCT03566407 | Prometheus Laboratories | N/A |
| Active Not Recruiting | A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Di NCT03466411 | Janssen Research & Development, LLC | Phase 2 / Phase 3 |
| Completed | Diet for Induction and Maintenance of Remission and Re-biosis in Crohn's Disease NCT02843100 | Prof. Arie Levine | N/A |
| Active Not Recruiting | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease NCT03105102 | AbbVie | Phase 3 |
| Terminated | A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients Wi NCT03478956 | Hoffmann-La Roche | Phase 1 |
| Active Not Recruiting | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participan NCT03345823 | AbbVie | Phase 3 |
| Completed | Phase 2a Study of PRV-6527 in Subjects With Moderately to Severely Active Crohn's Disease NCT03854305 | Provention Bio, Inc. | Phase 2 |
| Completed | A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's NCT03283085 | Shire | Phase 3 |
| Completed | Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF-06700841 In Subjects With Moderate To Sev NCT03395184 | Pfizer | Phase 2 |
| Completed | Proteomic Analysis of Crohn's Disease Macrophages in Response or Not to AIEC NCT03404557 | University Hospital, Clermont-Ferrand | — |
| Completed | An Analysis of the Relationship Between the Genetic Polymorphisms of Interleukin 12 Receptor Subunit Beta 1 an NCT07057856 | Second Affiliated Hospital of Wenzhou Medical University | — |
| Completed | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active C NCT03104413 | AbbVie | Phase 3 |
| Completed | A Trial of Yoga in Pediatric Inflammatory Bowel Disease NCT03338894 | Atlantic Health System | N/A |
| Completed | A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's NCT03345849 | AbbVie | Phase 3 |
| Completed | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Activ NCT03345836 | AbbVie | Phase 3 |
| Completed | Postmarketing Vedolizumab Milk-Only Lactation Study in Lactating Women With Active Ulcerative Colitis or Crohn NCT02559713 | Takeda | Phase 4 |
| Completed | Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in C NCT03223012 | AbbVie | — |
| Completed | Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) NCT03138655 | Takeda | Phase 2 |
| Recruiting | An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease an NCT03167437 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Terminated | A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Di NCT03017014 | AbbVie | — |
| Completed | Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for NCT03279081 | Tigenix S.A.U. | Phase 3 |
| Completed | Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease NCT03397108 | The Hospital for Sick Children | — |
| Completed | Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease. NCT03234907 | Takeda | Phase 3 |
| Active Not Recruiting | A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease NCT03251118 | Target PharmaSolutions, Inc. | — |
| Completed | Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdom NCT03155945 | Arena Pharmaceuticals | Phase 2 |
| Completed | Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases NCT02735941 | Medical University of Graz | — |
| Unknown | Upper Gastrointestinal Lesions in Crohn's Disease NCT03524144 | Sixth Affiliated Hospital, Sun Yat-sen University | N/A |
| Completed | A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's NCT03105128 | AbbVie | Phase 3 |
| Completed | GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation ) NCT02994836 | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Phase 4 |
| Terminated | Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease NCT02914600 | Galapagos NV | Phase 3 |
| Completed | Reduce Risk for Crohn's Disease Patients NCT02852694 | PIBD-Net | Phase 4 |
| Unknown | VEST: The UK Vedolizumab Real Life Experience Study in Inflammatory Bowel Disease NCT03257345 | University Hospital Southampton NHS Foundation Trust | — |
| Unknown | Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel D NCT03000101 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | N/A |
| Terminated | The Challenge Study: A Dietary Personalization Protocol for Patients With Crohn's Disease and Deep Remission NCT02930564 | Wolfson Medical Center | N/A |
| Unknown | The Role of MSC in the Treatment of Fistulas in Patients With Perianal Crohn's Disease NCT03056664 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 / Phase 3 |
| Unknown | Specific microRNAs as Potential Biomarker for Inflammatory Bowel Disease NCT03698500 | University Hospital Muenster | N/A |
| Completed | Predicting Response to Vedolizumab in Pediatric Inflammatory Bowel Diseases NCT02862132 | Shaare Zedek Medical Center | N/A |
| Completed | Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in NCT02896985 | AbbVie | — |
| Completed | A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's Disease NCT02891226 | Eli Lilly and Company | Phase 2 |
| Completed | The Crohn's Disease Exclusion Diet With Partial Enteral Nutrition or Alone in Adult Patients With Crohn's Dise NCT02231814 | Prof. Arie Levine | N/A |
| Completed | A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease NCT02976129 | VHsquared Ltd. | Phase 2 |
| Completed | Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's NCT02914561 | Galapagos NV | Phase 3 |
| Completed | A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Acti NCT02883452 | Celltrion | Phase 1 |
| Unknown | Relationship Between Prophylactic Drainage and Postoperative Complications (PPOI) in Crohn's Patients After Su NCT03815851 | Jinling Hospital, China | N/A |
| Unknown | The Effect of Diet on Microbial Profile and Disease Outcomes in Patients With Inflammatory Bowel Diseases NCT02858557 | Tel-Aviv Sourasky Medical Center | N/A |
| Terminated | MOlecular BIomarkers and Adherent and Invasive Escherichia Coli (AIEC) Detection Study In Crohn's Disease Pati NCT02882841 | Enterome | N/A |
| Completed | Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease NCT02630966 | Takeda | Phase 4 |
| Completed | Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease NCT02765256 | University of Pennsylvania | Phase 2 |
| Terminated | A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease NCT02641392 | Celgene | Phase 3 |
| Completed | PillCam SBC System Functionality in Established and Suspected IBD Patients NCT02742714 | Medtronic - MITG | N/A |
| Completed | Anti CT-P13 Antibody in Moderate to Severe Inflammatory Bowel Disease NCT02846961 | Kyungpook National University Hospital | — |
| Unknown | Mediterranean Diet as an add-on Therapy for Induction of Remission in Patients With Active Crohn's Disease NCT02825316 | michal roll | N/A |
| Terminated | Efficacy of CROWN in Repair and Maintenance of the Intestinal Mucosa in Patients With CD Receiving Anti-TNF Th NCT02793778 | Prometheus Laboratories | Phase 2 |
| Completed | Effect of a Comprehensive Nutrition Support Product on the Nutritional Status of Adults With Inflammatory Bowe NCT02801240 | National University of Natural Medicine | N/A |
| Completed | COmparison of MicroBiota AccordIng to Age in Crohn's Disease (COMeBACk) NCT02839317 | University Hospital, Lille | — |
| Completed | Osteopathy Non-manipulative in Patients With Crohn's Disease. NCT02763293 | University of Valencia | N/A |
| Completed | Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial) NCT02538341 | University of Alabama at Birmingham | Phase 2 |
| Unknown | Laparoscopy Combined With Enhanced Recovery Pathway NCT02777034 | Sir Run Run Shaw Hospital | N/A |
| Unknown | Early Surgery Versus Conservative Treatment in Patients With Ileocaecal Crohn's Disease NCT02716454 | Ondrej Ryska | N/A |
| Completed | Patient-Centred Innovations for Persons With Multimorbidity - Quebec NCT02789800 | Université de Sherbrooke | N/A |
| Completed | A Study of Long-term Effects of Vedolizumab Subcutaneous in Adults With Ulcerative Colitis and Crohn's Disease NCT02620046 | Takeda | Phase 3 |
| Completed | A Safety Study of Intravenously Administered UTTR1147A in Healthy Volunteers (HVs), Participants With Ulcerati NCT02749630 | Genentech, Inc. | Phase 1 |
| Completed | Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on P NCT02750800 | AbbVie | — |
| Terminated | Pharmacodynamic and Clinical Outcome Study of Mongersen in Patients With Crohn's Disease NCT02685683 | Celgene | Phase 2 |
| Completed | The Use of Small Bowel Ultrasound to Predict Response to Remicade Induction NCT02488005 | Icahn School of Medicine at Mount Sinai | N/A |
| Completed | Body Composition in Children With Inflammatory Bowel Disease NCT02745457 | Schneider Children's Medical Center, Israel | — |
| Completed | Imaging Biomarkers in Crohn's Associated Spondyloarthritis NCT02709694 | Hospital for Special Surgery, New York | — |
| Terminated | Corticosteroids With Vedolizumab in Crohn's Disease NCT02324699 | Icahn School of Medicine at Mount Sinai | Phase 4 |
| Unknown | Predictive Model of Clinical Outcomes Using Web-based Self-reporting Symptom Diary for Crohn's Disease NCT02760836 | Kyungpook National University Hospital | — |
| Withdrawn | The Efficacy of Topical Mesalazine Sustained-Release Tablets in Crohn's Disease Patients With Oral Ulcer NCT02769494 | Xijing Hospital of Digestive Diseases | Phase 3 |
| Enrolling By Invitation | Improving the Quality of Care for Adults With Inflammatory Bowel Disease NCT02791854 | Dartmouth-Hitchcock Medical Center | — |
| Terminated | To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease NCT02649075 | Entera Health, Inc | N/A |
| Completed | The Vitamin D in Pediatric Crohn's Disease NCT02186275 | St. Justine's Hospital | Phase 3 |
| Completed | Patient-Centred Innovations for Persons With Multimorbidity - Ontario NCT02742597 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N/A |
| Terminated | Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Cro NCT02574637 | AstraZeneca | Phase 2 |
| Completed | Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease (CD) NCT02611817 | Takeda | Phase 3 |
| Unknown | A Pilot Study of FFP104 in Subjects With Crohn's Disease NCT02465944 | Fast Forward Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Safety and Efficacy Study of Oral Ferric Maltol Compared to Intravenous Iron To Treat Iron Deficiency Anaemia NCT02680756 | Shield Therapeutics | Phase 3 |
| Unknown | The Efficiency of MSC in Refractory Crohn's Disease NCT02532738 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 2 / Phase 3 |
| Enrolling By Invitation | Fecal Microbiome Transplant NCT02636517 | Judith Kelsen | Phase 1 |
| Completed | OTIS Vedolizumab Pregnancy Exposure Registry NCT02678052 | Takeda | — |
| Completed | Evaluation of Digestive Damage and Associated Predictive Factors in Crohn's Disease 5 to 10 Years After Diagno NCT02549976 | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | N/A |
| Completed | Study of Bacteroides Thetaiotaomicron in Young People Aged 16 to 18 Years With Stable Crohn's Disease NCT02704728 | 4D pharma plc | N/A |
| Terminated | Volatiles in Exhaled Breath and Blood in Crohn's Disease: Validation Cohort NCT02641171 | Dartmouth-Hitchcock Medical Center | — |
| Unknown | The Diagnostic Methods of Early Postoperative Flare-up of Crohn's Disease NCT02578576 | Jinling Hospital, China | — |
| Unknown | A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease NCT02580617 | Anterogen Co., Ltd. | Phase 1 |
| Unknown | Does Clinical Response Correlate With Serum Certolizumab Levels? NCT02597829 | Shafran Gastroenterology Center | Phase 4 |
| Terminated | Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment NCT02622763 | Fundacion Clinic per a la Recerca Biomédica | Phase 1 |
| Unknown | Long-term Safety and Efficacy of FURESTEM-CD Inj. in Patients With Moderately Active Crohn's Disease(CD) NCT02926300 | Kang Stem Biotech Co., Ltd. | — |
| Completed | European Novel Motorized Spiral Endoscopy Trial NCT02965209 | Evangelisches Krankenhaus Düsseldorf | N/A |
| Completed | Multispectral Optoacoustic Tomography (MSOT) for the Evaluation of Disease Activity in Inflammatory Bowel Dise NCT02622139 | University of Erlangen-Nürnberg Medical School | N/A |
| Completed | Nutritional Therapy Study in Pediatric Crohn's Disease NCT02610101 | Seattle Children's Hospital | N/A |
| Completed | A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-met NCT02177071 | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Phase 4 |
| Completed | Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease NCT02531113 | Celgene | Phase 2 |
| Completed | Bologna IBD Markers NCT02580864 | Société des Produits Nestlé (SPN) | — |
| Completed | IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study NCT02847884 | University of Alberta | — |
| Completed | Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital NCT02998398 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Disea NCT02508012 | University Hospital, Montpellier | N/A |
| Completed | A First Time in Human Study in Healthy Volunteers and Patients NCT03010787 | VHsquared Ltd. | Phase 1 |
| Terminated | Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT) NCT02417974 | Boston Medical Center | Phase 2 |
| Completed | Home Versus Postal Testing for Faecal Calprotectin: a Feasibility Study NCT02542917 | King's College Hospital NHS Trust | — |
| Completed | Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Di NCT02499783 | AbbVie | Phase 3 |
| Completed | A Comparison of Ultrasound Guided Transversus Abdominis Plane Nerve Block Techniques NCT02538679 | Cedars-Sinai Medical Center | N/A |
| Terminated | Assessing the Tolerability of Oligosaccharide Supplementation in Patients With Crohn's Disease NCT02193750 | University of British Columbia | N/A |
| Completed | Extension Study of MT-1303 in Subjects With Crohn's Disease NCT02389790 | Tanabe Pharma Corporation | Phase 2 |
| Unknown | "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patie NCT02452151 | Onze Lieve Vrouwe Gasthuis | Phase 4 |
| Completed | Phenomics in Autoimmune and Inflammatory Diseases NCT02466217 | Assistance Publique - Hôpitaux de Paris | — |
| Completed | An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Pat NCT02451839 | AbbVie | — |
| Completed | Salvage Therapy With High/Low Methotrexate for Loss of Response to Infliximab Dose Escalation NCT02269358 | Prof. Arie Levine | Phase 4 |
| Completed | Reduced Appetite in Crohn's Disease: The Role of the Brain in the Control of Food Intake NCT02772458 | University of Nottingham | N/A |
| Completed | The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness NCT02423512 | Icahn School of Medicine at Mount Sinai | — |
| Terminated | The Value of I-Scan and Confocal Laser Endomicroscopy for the Assessment of Chronic Inflammatory Bowel Disease NCT02481687 | University of Medicine and Pharmacy Craiova | — |
| Completed | Medication Adherence in Patients With Inflammatory Bowel Disease (IBD) NCT02620514 | Emory University | N/A |
| Terminated | Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator NCT02413047 | Indiana University | N/A |
| Completed | Pediatric Crohn's Disease AdalImumab Level-based Optimization Treatment (PAILOT) Trial NCT02256462 | Schneider Children's Medical Center, Israel | Phase 4 |
| Unknown | SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins NCT02383953 | St Stephens Aids Trust | — |
| Completed | Threonine Requirement in IBD Adults and Healthy Adult Controls NCT02423460 | Société des Produits Nestlé (SPN) | N/A |
| Terminated | Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease NCT02405442 | Gilead Sciences | Phase 2 |
| Completed | Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Inflammatory Bowel Disease NCT02539368 | Pfizer | — |
| Completed | Acupuncture Treatment for Active Crohn's Disease NCT02559037 | Shanghai Institute of Acupuncture, Moxibustion and Meridian | N/A |
| Completed | Eating Behaviour in Crohn's Disease NCT02379117 | University of Nottingham | — |
| Completed | Top-down Infliximab Study in Kids With Crohn's Disease NCT02517684 | Erasmus Medical Center | Phase 4 |
| Terminated | Trial of High Dose Vitamin D in Patient's With Crohn's Disease NCT02208310 | University of Michigan | Phase 4 |
| Completed | Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease NCT02425111 | Takeda | Phase 3 |
| Completed | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic NCT02365649 | AbbVie | Phase 2 |
| Completed | Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease NCT02378688 | Tanabe Pharma Corporation | Phase 2 |
| Withdrawn | High-dose Cyclophosphamide for Severe Refractory Crohn Disease NCT01836289 | Johns Hopkins University | Phase 1 / Phase 2 |
| Terminated | Corticosteroid Dosage for Crohn's Disease Flare NCT02392286 | Yale University | Phase 4 |
| Completed | Capsule Colonoscopy in Crohn's Disease and Its Correlation With Conventional Colonoscopy and Faecal Calprotect NCT02624414 | Melbourne Health | N/A |
| Completed | Trial on Impact of HealthPROMISE Mobile App on Inflammatory Bowel Disease Care and Quality of Life NCT02322307 | Icahn School of Medicine at Mount Sinai | N/A |
| Withdrawn | Contrast-Enhanced Ultrasound in Human Crohn's Disease NCT02061163 | University of Michigan | Phase 1 / Phase 2 |
| Unknown | RED-FLAGS Index Validation in Crohn's Disease Patients NCT02940054 | Istituto Clinico Humanitas | — |
| Terminated | Fecal Microbial Transplant in Pediatric Crohn's Disease NCT02272868 | Seattle Children's Hospital | Phase 1 / Phase 2 |
| Completed | Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease NCT06299631 | University Hospital, Montpellier | — |
| Unknown | Standardized Fecal Microbiota Transplantation for Inflammatory Bowel Disease NCT02335281 | Yanling Wei | Phase 2 |
| Completed | Cyclic Exclusive Enteral Nutrition as Maintenance Therapy for Pediatric Crohn's Disease NCT02201693 | Assistance Publique - Hôpitaux de Paris | N/A |
| Terminated | To Evaluate the Safety and Efficacy of Remsima™ in Patients With Crohn's Disease (CD) or Ulcerative Colitis (U NCT02326155 | Celltrion | — |
| Unknown | Vagus Nerve Stimulation in Crohn's Disease NCT02311660 | SetPoint Medical Corporation | N/A |
| Withdrawn | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 I NCT02249078 | Eisai Inc. | Phase 1 |
| Completed | Curcumin Associated With Thiopurin in the Prevention of Post-op Recurrence in Crohn Disease NCT02255370 | University Hospital, Clermont-Ferrand | Phase 3 |
| Unknown | The Impact of 6MP Metabolite Levels on Infliximab Pharmacokinetics and Anti-infliximab Antibodies in Crohn's D NCT02453607 | Ernest Seidman | — |
| Completed | The Impact of "Crohn's Disease-TReatment-with-EATing" Diet and Exclusive Enteral Nutrition on Healthy Gut Bact NCT02426567 | University of Glasgow | N/A |